ADVERTISEMENT

Conference Report

ASCO 2022 – Anti-EGFR or anti-VEGF? The question in RAS wild-type colorectal cancer

Cristina Ferrario — Agenzia Zoe   |   07 June 2022

Takeaway

  • In patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC), panitumumab led to better overall survival (OS) compared to bevacizumab in combination with standard chemotherapy (mFOLFOX6), especially in left-sided tumours.
  • Panitumumab plus mFOLFOX6 demonstrated the longest survival ever reported in the first-line unresectable mCRC phase 3 trials.
  • This study...

          

November Challenge

Ends in 1d 5h
left
right

Topic Challenges

left
right